Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

To be considered for this study, you would need to have one of the following types of advanced cancer: triple negative breast cancer, head and neck cancer, a type of ovarian cancer (high-grade serous), or kidney cancer. For these conditions, the cancer should ideally not be treatable with surgery aiming for a cure. If you have head and neck cancer, you might also be eligible if you are planned to have surgery that aims to cure your cancer.

Additionally, you should have already received, or not be suitable for, standard treatments for your specific cancer type. For example, some breast cancer patients might have finished their standard treatments or refused them, or stopped immunotherapy due to side effects. For head and neck cancer, you might have had chemotherapy with or without radiotherapy, or be unable to have platinum-based chemotherapy. The study will look for patients whose disease can be measured by medical scans.

The study welcomes both men and women, and you need to be at least 18 years old. These are general guidelines, and the full details will be discussed with you by the study doctor to see if this trial is a good fit for your individual situation.

If you join this study, you will receive the Modi-1 Moditope treatment, which will be given using a special small device called NanoPass that delivers the treatment just under the skin. Depending on which part of the study you are in, you might receive Modi-1 Moditope by itself or together with other approved cancer drugs like pembrolizumab, which might be given through a drip. The exact schedule of your visits and treatments will depend on your condition and the specific arm of the study you are in, but it will involve regular appointments for treatment, assessments, and check-ups.

These assessments will include physical examinations, blood tests, and scans to monitor your cancer and check how you are responding to the treatment. The research team will also be looking at how your immune system responds to the vaccine. There will be follow-up appointments after your treatment period to see how you are doing in the long term. The total duration of your participation will vary but will include active treatment phases and monitoring periods.